Summary & Overview
HCPCS M0239: Intravenous Infusion of Bamlanivimab with Monitoring
HCPCS Level II code M0239 represents the intravenous infusion of bamlanivimab-xxxx and includes the infusion procedure plus post-administration monitoring. This code captures bundled drug administration and immediate observation services for a monoclonal antibody infusion, a service of national relevance given widespread use of monoclonal antibody therapies in outpatient settings. Payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical and billing context for M0239, including typical sites of service, how the code is used to document bundled infusion and monitoring encounters, and what to expect from payer coverage patterns. The publication provides benchmarks where available, summarizes relevant policy updates affecting monoclonal antibody infusions, and outlines common billing considerations tied to infusion services. Data not available in the input is noted where applicable. The focus is national; state-level variation is not included.
Billing Code Overview
HCPCS Level II code M0239 describes intravenous infusion of bamlanivimab-xxxx, including infusion and post-administration monitoring. The service type is monoclonal antibody intravenous infusion with observation, reflecting a combined drug administration and monitoring encounter. The typical site of service is outpatient infusion settings, such as ambulatory infusion centers, hospital outpatient departments, physician office infusion suites, or other outpatient clinics equipped for intravenous monoclonal antibody administration.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with multiple comorbidities (type 2 diabetes, chronic kidney disease stage 3, and hypertension) presents to an outpatient infusion center within the manufacturer- and public-health-specified timeframe after testing positive for SARS-CoV-2 and experiencing mild-to-moderate COVID-19 symptoms. The ordering clinician documents eligibility for monoclonal antibody therapy and obtains informed consent. On arrival, nursing performs baseline vital signs, reviews allergies, and establishes IV access. The provider administers M0239 — intravenous infusion of bamlanivimab — with continuous monitoring during infusion and for a minimum post-administration observation period to watch for infusion reactions or anaphylaxis. Emergency medications and equipment are available. After monitoring, discharge instructions and return precautions are provided, and documentation includes indication, dose, lot number, infusion start/stop times, patient tolerance, and post-infusion status for billing and quality reporting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component | Use when reporting only the professional component by the physician for services that have separate professional and technical components (rare for infused drug administration). |